Neumann AU, Tubiana R, Calvez V, Robert C, Autran B, Katlama C; Conference on Retroviruses and Opportunistic Infections.
Program Abstr 5th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 5th 1998 Chic Ill. 1998 Feb 1-5; 5th: 176 (abstract no. 517).
Bar-Ilan University, Ramat-Gan, Israel.
Study of viral dynamics has become an important tool in understanding HIV infection and antiviral therapy. However, up to now it was limited to analyzing the decline of various viral compartments following anti-viral therapy. Here, we present for the first time an analysis of the dynamics during viral rebound following therapy interruption. We have frequently sampled blood from 8 naive patients that have undergone triple-drug anti-HIV therapy (Indinavir/AZT/3TC) for 28 days; then interrupted therapy for 28 days; at which time they re-started the same therapy. All Patients had a rapid viral decline during the first 28 days of therapy with average exponential rates of -0.43/day and -0.09/day in the periods 0-7 days and 7-28 days respectively. Upon interruption of therapy there was a 4-7 days delay before viral rebound has started. At that point viral growth replication has rapidly grown with an average exponential rate of 0.47/day. Viral load has reached an average of 1.25 times the baseline viral load after 28 days of therapy interruption. Upon re-initialization of therapy, viral load again rapidly dropped with average rates of -0.46/day and -0.09/day in the periods 0-7 days and 7-28 days respectively. These slopes are significantly comparable (p greater than 0.5) to those of the initial therapy period. Thus, therapy interruption did not have any bad influence on the drug's ability to block replication. Analysis of the data shows that both the death rate of infected cells and the replication rate of the virus are positively correlated with viral load. This indicates that rapid viral replication is the main factor leading to progression.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Antiretroviral Therapy, Highly Active
- Antiviral Agents
- Disease Progression
- Drug Therapy, Combination
- HIV
- HIV Infections
- HIV Seropositivity
- Humans
- Indinavir
- Lamivudine
- Pharmaceutical Preparations
- Viral Load
- Zidovudine
- drug therapy
- therapy
Other ID:
UI: 102236101
From Meeting Abstracts